New Perspectives on the Basal Forebrain Cholinergic System in Alzheimer's Disease

Overview

Journal Neurosci Biobehav Rev

Specialties Neurology
Psychology
Social Sciences

Date 2023 Apr 22

PMID 37086935

Authors

Anne S Berry

Theresa M Harrison

Affiliations

Soon will be listed here.

Abstract

The basal forebrain cholinergic system (BFCS) has long been implicated in age-related cognitive changes and the pathophysiology of Alzheimer's disease (AD). Limitations of cholinergic interventions helped to inspire a shift away from BFCS in AD research. A resurgence in interest in the BFCS following methodological and analytical advances has resulted in a call for the BFCS to be examined in novel frameworks. We outline the basic structure and function of the BFCS, its role in supporting cognitive and affective function, and its vulnerability to aging and AD. We consider the BFCS in the context of the amyloid hypothesis and evolving concepts in AD research: resilience and resistance to pathology, selective neuronal vulnerability, trans-synaptic pathology spread and sleep health. We highlight 1) the potential role of the BFCS in cognitive resilience, 2) recent work refining understanding about the selective vulnerability of BFCS to AD, 3) BFCS connectivity that suggests it is related to tau spreading and neurodegeneration and 4) the gap between BFCS involvement in AD and sleep-wake cycles.

Citing Articles

Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.

Ortiz-Islas E, Montes P, Rodriguez-Perez C, Ruiz-Sanchez E, Sanchez-Barbosa T, Pichardo-Rojas D Pharmaceutics. 2025; 17(1).

PMID: 39861773 PMC: 11768419. DOI: 10.3390/pharmaceutics17010128.

Enhanced prefrontal nicotinic signaling as evidence of active compensation in Alzheimer's disease models.

Power S, Venkatesan S, Qu S, McLaurin J, Lambe E Transl Neurodegener. 2024; 13(1):58.

PMID: 39623428 PMC: 11613856. DOI: 10.1186/s40035-024-00452-7.

Examining resilience to Alzheimer's disease through the lens of monoaminergic neuromodulator systems.

Crawford J, Berry A Trends Neurosci. 2024; 47(11):892-903.

PMID: 39368845 PMC: 11563896. DOI: 10.1016/j.tins.2024.09.004.

Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?.

Zhang S, Lu J, Jin Z, Xu H, Zhang D, Chen J Front Pharmacol. 2024; 15:1459655.

PMID: 39355779 PMC: 11442227. DOI: 10.3389/fphar.2024.1459655.

A Bioinformatics-Based Study on Methylation Alterations of the FBLN1 Gene in Hippocampal Tissue of Alzheimer's Disease Model DKO and DTG Mice.

Tang R, Jian Y, Hu Z, Li L, Wang H, Miao P Int J Mol Sci. 2024; 25(16).

PMID: 39201719 PMC: 11354892. DOI: 10.3390/ijms25169036.

References

Gaykema R, Luiten P, Nyakas C, Traber J . Cortical projection patterns of the medial septum-diagonal band complex. J Comp Neurol. 1990; 293(1):103-24. DOI: 10.1002/cne.902930109. View

Grothe M, Heinsen H, Teipel S . Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol Aging. 2012; 34(4):1210-20. PMC: 4058576. DOI: 10.1016/j.neurobiolaging.2012.10.018. View

Beck J, Madaj Z, Cheema C, Kara B, Bennett D, Schneider J . Co-expression network analysis of frontal cortex during the progression of Alzheimer's disease. Cereb Cortex. 2022; 32(22):5108-5120. PMC: 9667180. DOI: 10.1093/cercor/bhac001. View

Knipper M, Da Penha Berzaghi M, Blochl A, Breer H, Thoenen H, Lindholm D . Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur J Neurosci. 1994; 6(4):668-71. DOI: 10.1111/j.1460-9568.1994.tb00312.x. View

Mintzer M, Griffiths R . Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes. Exp Clin Psychopharmacol. 2003; 11(1):56-72. DOI: 10.1037//1064-1297.11.1.56. View

Ballinger E, Ananth M, Talmage D, Role L . Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron. 2016; 91(6):1199-1218. PMC: 5036520. DOI: 10.1016/j.neuron.2016.09.006. View

Rossor M, Garrett N, Johnson A, Mountjoy C, Roth M, Iversen L . A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain. 1982; 105(Pt 2):313-30. DOI: 10.1093/brain/105.2.313. View

Teipel S, Heinsen H, Amaro Jr E, Grinberg L, Krause B, Grothe M . Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging. 2013; 35(3):482-91. PMC: 4120959. DOI: 10.1016/j.neurobiolaging.2013.09.029. View

Wolf B, Wertkin A, Jolly Y, Yasuda R, Wolfe B, Konrad R . Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem. 1995; 270(9):4916-22. DOI: 10.1074/jbc.270.9.4916. View

10.

Price J, Morris J . Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999; 45(3):358-68. DOI: 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x. View

11.

Snyder H, Miyake A, Hankin B . Advancing understanding of executive function impairments and psychopathology: bridging the gap between clinical and cognitive approaches. Front Psychol. 2015; 6:328. PMC: 4374537. DOI: 10.3389/fpsyg.2015.00328. View

12.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

13.

Rossner S, Ueberham U, Schliebs R, Perez-Polo J, Bigl V . The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol. 1998; 56(5):541-69. DOI: 10.1016/s0301-0082(98)00044-6. View

14.

Zhang B, Veasey S, Wood M, Leng L, Kaminski C, Leight S . Impaired rapid eye movement sleep in the Tg2576 APP murine model of Alzheimer's disease with injury to pedunculopontine cholinergic neurons. Am J Pathol. 2005; 167(5):1361-9. PMC: 1603771. DOI: 10.1016/S0002-9440(10)61223-0. View

15.

Schmitz T, Mur M, Aghourian M, Bedard M, Nathan Spreng R . Longitudinal Alzheimer's Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections. Cell Rep. 2018; 24(1):38-46. PMC: 8840819. DOI: 10.1016/j.celrep.2018.06.001. View

16.

Sala R, Viegi A, Rossi F, Pizzorusso T, Bonanno G, Raiteri M . Nerve growth factor and brain-derived neurotrophic factor increase neurotransmitter release in the rat visual cortex. Eur J Neurosci. 1998; 10(6):2185-91. DOI: 10.1046/j.1460-9568.1998.00227.x. View

17.

Bliwise D, Tinklenberg J, Yesavage J, Davies H, Pursley A, Petta D . REM latency in Alzheimer's disease. Biol Psychiatry. 1989; 25(3):320-8. DOI: 10.1016/0006-3223(89)90179-0. View

18.

Wolf D, Grothe M, Fischer F, Heinsen H, Kilimann I, Teipel S . Association of basal forebrain volumes and cognition in normal aging. Neuropsychologia. 2013; 53:54-63. DOI: 10.1016/j.neuropsychologia.2013.11.002. View

19.

Matchett B, Grinberg L, Theofilas P, Murray M . The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease. Acta Neuropathol. 2021; 141(5):631-650. PMC: 8043919. DOI: 10.1007/s00401-020-02248-1. View

20.

Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L . Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704-6. DOI: 10.1038/349704a0. View